{"hands_on_practices": [{"introduction": "The hierarchy of evidence places randomized trials above observational studies primarily because of confounding. But what exactly is confounding bias, and how large can it be? This first exercise makes the abstract concept of confounding tangible. By working through a hypothetical scenario with a known data-generating mechanism, you will calculate both the true causal effect and the biased \"crude\" association, allowing you to isolate and quantify the confounding bias precisely. [@problem_id:4598875]", "problem": "Consider the epistemic rationale behind the hierarchy of evidence in epidemiology: randomized controlled trials (RCTs) are placed above observational studies primarily because randomization can eliminate confounding by balancing prognostic factors across exposure groups. To make this precise in a simple setting, consider a binary exposure $E \\in \\{0,1\\}$, a binary outcome $Y \\in \\{0,1\\}$, and a single binary confounder $Z \\in \\{0,1\\}$. Assume the Stable Unit Treatment Value Assumption (SUTVA), consistency, and positivity. Use the law of total probability and Bayes’ rule as fundamental tools.\n\nYou are given the following structural table of probabilities that fully specifies the data-generating mechanism:\n- $P(Z=1) = 0.3$, $P(Z=0) = 0.7$.\n- $P(E=1 \\mid Z=1) = 0.8$, $P(E=1 \\mid Z=0) = 0.2$.\n- $P(Y=1 \\mid E=1, Z=1) = 0.25$, $P(Y=1 \\mid E=0, Z=1) = 0.20$.\n- $P(Y=1 \\mid E=1, Z=0) = 0.15$, $P(Y=1 \\mid E=0, Z=0) = 0.10$.\n\nDefine the crude (unadjusted) risk difference as the observed difference in outcome risks between the exposed and unexposed, ignoring $Z$. Define the causal risk difference as the contrast $P(Y^{1}=1) - P(Y^{0}=1)$, where $Y^{e}$ denotes the potential outcome under $E=e$, evaluated for the target population defined by the marginal distribution of $Z$. Using first principles, compute the signed confounding bias as the crude risk difference minus the causal risk difference. Report the final value as a decimal, rounded to four significant figures. No units are required.", "solution": "The problem requires the calculation of the confounding bias, defined as the difference between the crude risk difference and the causal risk difference. We are given a fully specified probabilistic model for a binary exposure $E$, a binary outcome $Y$, and a binary confounder $Z$.\n\nThe given probabilities are:\n- $P(Z=1) = 0.3$, which implies $P(Z=0) = 1 - 0.3 = 0.7$.\n- $P(E=1 \\mid Z=1) = 0.8$, which implies $P(E=0 \\mid Z=1) = 1 - 0.8 = 0.2$.\n- $P(E=1 \\mid Z=0) = 0.2$, which implies $P(E=0 \\mid Z=0) = 1 - 0.2 = 0.8$.\n- $P(Y=1 \\mid E=1, Z=1) = 0.25$.\n- $P(Y=1 \\mid E=0, Z=1) = 0.20$.\n- $P(Y=1 \\mid E=1, Z=0) = 0.15$.\n- $P(Y=1 \\mid E=0, Z=0) = 0.10$.\n\nThe confounding bias is defined as:\n$$\n\\text{Bias} = \\text{Crude Risk Difference} - \\text{Causal Risk Difference}\n$$\nwhere:\n- Crude Risk Difference is $P(Y=1 \\mid E=1) - P(Y=1 \\mid E=0)$.\n- Causal Risk Difference is $P(Y^{1}=1) - P(Y^{0}=1)$.\n\nWe will compute each term separately.\n\n**1. Causal Risk Difference**\n\nThe causal risk difference is the difference in the potential outcome probabilities $P(Y^e=1)$. We compute these using the g-formula (standardization), which involves averaging the stratum-specific outcomes, weighted by the marginal distribution of the confounder $Z$ in the target population.\n$$\nP(Y^e=1) = \\sum_{z \\in \\{0,1\\}} P(Y^e=1 \\mid Z=z) P(Z=z)\n$$\nUnder the assumption of consistency ($Y=Y^e$ when $E=e$) and conditional exchangeability given $Z$ ($Y^e \\perp E \\mid Z$), this becomes:\n$$\nP(Y^e=1) = \\sum_{z \\in \\{0,1\\}} P(Y=1 \\mid E=e, Z=z) P(Z=z)\n$$\nFor $e=1$:\n$$\nP(Y^1=1) = P(Y=1 \\mid E=1, Z=1)P(Z=1) + P(Y=1 \\mid E=1, Z=0)P(Z=0)\n$$\n$$\nP(Y^1=1) = (0.25)(0.3) + (0.15)(0.7) = 0.075 + 0.105 = 0.18\n$$\nFor $e=0$:\n$$\nP(Y^0=1) = P(Y=1 \\mid E=0, Z=1)P(Z=1) + P(Y=1 \\mid E=0, Z=0)P(Z=0)\n$$\n$$\nP(Y^0=1) = (0.20)(0.3) + (0.10)(0.7) = 0.060 + 0.070 = 0.13\n$$\nThe Causal Risk Difference is:\n$$\nP(Y^1=1) - P(Y^0=1) = 0.18 - 0.13 = 0.05\n$$\n\n**2. Crude Risk Difference**\n\nThe crude risk difference, $P(Y=1 \\mid E=1) - P(Y=1 \\mid E=0)$, is the associational difference observed in the data without adjusting for the confounder $Z$. We must first calculate the marginal probabilities of the outcome conditional on the exposure. This can be done using the law of total probability and Bayes' rule.\n\nFirst, we find the marginal probability of exposure, $P(E=1)$:\n$$\nP(E=1) = P(E=1 \\mid Z=1)P(Z=1) + P(E=1 \\mid Z=0)P(Z=0)\n$$\n$$\nP(E=1) = (0.8)(0.3) + (0.2)(0.7) = 0.24 + 0.14 = 0.38\n$$\nThus, $P(E=0) = 1 - P(E=1) = 1 - 0.38 = 0.62$.\n\nNext, we calculate the joint probabilities $P(Y=1, E=1)$ and $P(Y=1, E=0)$ by marginalizing over $Z$:\n$$\nP(Y=1, E=1) = P(Y=1, E=1, Z=1) + P(Y=1, E=1, Z=0)\n$$\nUsing the chain rule, $P(A,B,C) = P(A|B,C)P(B|C)P(C)$:\n$$\nP(Y=1, E=1, Z=1) = P(Y=1 \\mid E=1, Z=1) P(E=1 \\mid Z=1) P(Z=1) = (0.25)(0.8)(0.3) = 0.06\n$$\n$$\nP(Y=1, E=1, Z=0) = P(Y=1 \\mid E=1, Z=0) P(E=1 \\mid Z=0) P(Z=0) = (0.15)(0.2)(0.7) = 0.021\n$$\nSo, $P(Y=1, E=1) = 0.06 + 0.021 = 0.081$.\n\nSimilarly for $E=0$:\n$$\nP(Y=1, E=0, Z=1) = P(Y=1 \\mid E=0, Z=1) P(E=0 \\mid Z=1) P(Z=1) = (0.20)(0.2)(0.3) = 0.012\n$$\n$$\nP(Y=1, E=0, Z=0) = P(Y=1 \\mid E=0, Z=0) P(E=0 \\mid Z=0) P(Z=0) = (0.10)(0.8)(0.7) = 0.056\n$$\nSo, $P(Y=1, E=0) = 0.012 + 0.056 = 0.068$.\n\nNow we can compute the crude risks using the definition of conditional probability $P(A \\mid B) = P(A,B)/P(B)$:\n$$\nP(Y=1 \\mid E=1) = \\frac{P(Y=1, E=1)}{P(E=1)} = \\frac{0.081}{0.38} \\approx 0.213157...\n$$\n$$\nP(Y=1 \\mid E=0) = \\frac{P(Y=1, E=0)}{P(E=0)} = \\frac{0.068}{0.62} \\approx 0.109677...\n$$\nThe Crude Risk Difference is:\n$$\nP(Y=1 \\mid E=1) - P(Y=1 \\mid E=0) = \\frac{0.081}{0.38} - \\frac{0.068}{0.62} \\approx 0.213157... - 0.109677... \\approx 0.103480...\n$$\n\n**3. Confounding Bias**\n\nFinally, we compute the signed confounding bias:\n$$\n\\text{Bias} = \\text{Crude Risk Difference} - \\text{Causal Risk Difference}\n$$\n$$\n\\text{Bias} \\approx 0.103480... - 0.05 = 0.053480...\n$$\nRounding the result to four significant figures gives $0.05348$.", "answer": "$$\\boxed{0.05348}$$", "id": "4598875"}, {"introduction": "In an ideal randomized trial, confounding is eliminated by the study design. In observational research, we must rely on statistical adjustment, but which variables should we control for? Adjusting for the wrong variables can fail to remove bias or even introduce new biases. This practice introduces Directed Acyclic Graphs (DAGs) as a formal tool to navigate this complexity and identify a valid adjustment set to control for confounding pathways. [@problem_id:4598909]", "problem": "A health system is evaluating the causal effect of an antihypertensive therapy $A$ (initiation at baseline; yes/no) on a composite cardiovascular outcome $Y$ (occurrence within one year; yes/no) using an observational cohort. The following variables are measured at baseline: a clinician-facing risk score $Z$ (higher values reflect higher predicted risk and tend to influence prescribing), a genetic factor $L$ (not directly affecting outcomes but influencing the risk score and prescribing), and a post-treatment mediator $M$ (early blood pressure reduction, thought to transmit part of the effect of $A$ on $Y$). Assume the population mechanism is captured by the directed acyclic graph (DAG) with arrows\n$L \\to A$, $L \\to Z$, $Z \\to A$, $Z \\to Y$, $Z \\to M$, $A \\to M$, and $M \\to Y$,\nand possibly a direct arrow $A \\to Y$. There are no other variables, and there are no additional unmeasured common causes beyond those represented. Assume the DAG is acyclic and the standard causal Markov and faithfulness assumptions hold.\n\nStarting from the core definitions—namely, that a backdoor path from $A$ to $Y$ is any path that starts with an arrow into $A$, and that d-separation blocks a path if, conditional on a set, the path contains a noncollider that is conditioned on or a collider that is not conditioned on nor any of its descendants—use d-separation to determine whether conditioning on $Z$ blocks all backdoor paths from $A$ to $Y$. Then, align this conclusion with the epidemiologic hierarchy of evidence, where randomized controlled trials (RCTs) generally occupy the highest rung because randomization severs all incoming arrows into the exposure.\n\nWhich single option best captures both the d-separation conclusion and its implication for the hierarchy of evidence?\n\nA. Conditioning on $Z$ blocks all backdoor paths from $A$ to $Y$ in the stated DAG, leaving only frontdoor (causal) paths via $M$ and any direct $A \\to Y$ effect; therefore, a properly adjusted observational analysis (conditioning on $Z$ but not on $M$ when targeting the total effect) can identify the causal effect under these assumptions, yet in the hierarchy of evidence it still sits below a randomized controlled trial because randomization would more generally remove all incoming arrows into $A$.\n\nB. Conditioning on $Z$ fails to block the backdoor path $A \\leftarrow L \\to Y$, so residual confounding by $L$ remains; hence, the observational estimate is biased and the hierarchy of evidence offers no advantage to randomized controlled trials in this setting.\n\nC. Conditioning on $Z$ opens a collider at $Z$ because $L \\to Z \\leftarrow A$, creating bias; instead, one should condition on $M$ to block backdoor paths and thereby achieve evidence equivalent to a randomized controlled trial.\n\nD. Conditioning on $Z$ blocks the backdoor paths but also blocks the causal pathway through $M$; thus, to recover the total causal effect, one must additionally condition on $M$, which elevates the observational evidence to the same level as a randomized controlled trial in the hierarchy of evidence.", "solution": "## Problem Validation\n\n### Step 1: Extract Givens\n-   **Exposure:** Antihypertensive therapy $A$ (yes/no).\n-   **Outcome:** Composite cardiovascular outcome $Y$ (yes/no).\n-   **Study Type:** Observational cohort.\n-   **Baseline Variables:**\n    -   $Z$: A clinician-facing risk score.\n    -   $L$: A genetic factor.\n-   **Post-treatment Variable:**\n    -   $M$: A mediator (early blood pressure reduction).\n-   **Causal Structure (Directed Acyclic Graph - DAG):**\n    -   The arrows are: $L \\to A$, $L \\to Z$, $Z \\to A$, $Z \\to Y$, $Z \\to M$, $A \\to M$, and $M \\to Y$.\n    -   There may be a direct arrow $A \\to Y$.\n    -   There are no other variables and no unmeasured common causes.\n-   **Assumptions:**\n    -   The DAG is acyclic.\n    -   The standard causal Markov and faithfulness assumptions hold.\n-   **Definitions Provided:**\n    -   **Backdoor path:** A path from $A$ to $Y$ starting with an arrow into $A$.\n    -   **d-separation:** A path is blocked by a conditioning set if it contains a non-collider that is in the set, or a collider that is not in the set and none of whose descendants are in the set.\n-   **Question:** Use d-separation to check if conditioning on $Z$ blocks all backdoor paths from $A$ to $Y$, and relate this to the hierarchy of evidence concerning Randomized Controlled Trials (RCTs).\n\n### Step 2: Validate Using Extracted Givens\nThe problem is well-defined within the framework of causal inference using Directed Acyclic Graphs (DAGs), a standard and rigorous methodology in epidemiology and related fields.\n\n-   **Scientifically Grounded:** The concepts of confounding, mediation, backdoor paths, d-separation, and the hierarchy of evidence are fundamental principles in modern epidemiology and statistics. The scenario described is a plausible and common problem in pharmacoepidemiology. There are no violations of scientific principles.\n-   **Well-Posed:** The problem provides a complete DAG structure and a clear set of assumptions (no unmeasured confounding, Markov property, faithfulness). The question is precise and asks for a conclusion that can be derived deterministically from the given information and definitions. A unique, stable, and meaningful solution exists.\n-   **Objective:** The language is formal and unambiguous. The variables and their relationships are defined explicitly through the DAG. There are no subjective or opinion-based statements.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. It is a standard application of causal inference principles. The solution process can proceed.\n\n## Derivation of the Correct Answer\n\nThe task has two parts: first, to perform a d-separation analysis to determine if conditioning on $Z$ is sufficient to control for confounding, and second, to place this finding in the context of the hierarchy of evidence.\n\n### Part 1: d-Separation Analysis\n\nA causal effect of $A$ on $Y$ is identifiable if we can block all non-causal (backdoor) paths between them, while leaving all causal (frontdoor) paths open.\n\n**1. Identify Backdoor Paths:**\nAccording to the provided definition, a backdoor path is a path between $A$ and $Y$ that begins with an arrow pointing into $A$. The arrows pointing into $A$ are $L \\to A$ and $Z \\to A$. We list all paths from $A$ to $Y$ that start with these arrows.\n\n-   Path starting with $A \\leftarrow Z$:\n    1.  $A \\leftarrow Z \\to Y$. This is a backdoor path where $Z$ is a common cause of $A$ and $Y$.\n    2.  $A \\leftarrow Z \\to M \\to Y$. This is a backdoor path where $Z$ is a common cause of $A$ and a variable on a causal pathway to $Y$.\n\n-   Path starting with $A \\leftarrow L$:\n    3.  $A \\leftarrow L \\to Z \\to Y$. This is a backdoor path.\n    4.  $A \\leftarrow L \\to Z \\to M \\to Y$. This is another backdoor path.\n\nNote that the problem stipulates that $L$ does not directly affect outcomes, which means there are no arrows such as $L \\to Y$ or $L \\to M$. Therefore, the four paths listed above are the only backdoor paths in this DAG.\n\n**2. Test for Blockage by Conditioning on $Z$:**\nWe now check if conditioning on the set $\\{Z\\}$ blocks these four paths according to the rule of d-separation.\n\n-   For path $1$, $A \\leftarrow Z \\to Y$:\n    The node $Z$ is a non-collider (a chain node) on this path. Since we are conditioning on $Z$, this path is **blocked**.\n\n-   For path $2$, $A \\leftarrow Z \\to M \\to Y$:\n    The node $Z$ is a non-collider (a chain node) on this path. Since we are conditioning on $Z$, this path is **blocked**.\n\n-   For path $3$, $A \\leftarrow L \\to Z \\to Y$:\n    The node $Z$ is a non-collider (a chain node) on this path. Since we are conditioning on $Z$, this path is **blocked**.\n\n-   For path $4$, $A \\leftarrow L \\to Z \\to M \\to Y$:\n    The node $Z$ is a non-collider (a chain node) on this path. Since we are conditioning on $Z$, this path is **blocked**.\n\n**Conclusion of Part 1:** Conditioning on $Z$ successfully blocks all backdoor paths from $A$ to $Y$. This satisfies the backdoor criterion for identifying the causal effect of $A$ on $Y$.\n\n**3. Identify Causal Paths:**\nCausal paths are directed paths from $A$ to $Y$.\n-   Direct path: $A \\to Y$ (if it exists).\n-   Indirect path: $A \\to M \\to Y$.\n\nConditioning on $Z$ does not block these paths, as $Z$ is not a node on either path. This is desired, as we wish to estimate the total effect transmitted through these paths. To estimate the *total* causal effect, one must *not* condition on the mediator $M$, as doing so would block the indirect causal path $A \\to M \\to Y$.\n\n### Part 2: Hierarchy of Evidence\n\nAn ideal Randomized Controlled Trial (RCT) works by randomly assigning the exposure $A$. In the language of DAGs, this is equivalent to severing all arrows that point into $A$. In this case, randomization would remove the arrows $L \\to A$ and $Z \\to A$. With no arrows entering $A$, there can be no backdoor paths, and thus no confounding, by design.\n\nOur observational analysis, by conditioning on $Z$, can identify the causal effect *under the assumption that the given DAG is correct and complete*. This means we assume there are no other confounders, measured or unmeasured. This is a strong, and often untestable, assumption.\n\nAn RCT does not rely on this assumption. Randomization balances the distribution of *all* potential confounders, known and unknown, between the treatment and control groups. Therefore, even if our observational study is perfectly designed and analyzed according to the specified DAG, it remains on a lower rung of the hierarchy of evidence than an RCT. The RCT's strength lies in its robustness against our ignorance of the true, complete causal structure.\n\n## Option-by-Option Analysis\n\n**A. Conditioning on $Z$ blocks all backdoor paths from $A$ to $Y$ in the stated DAG, leaving only frontdoor (causal) paths via $M$ and any direct $A \\to Y$ effect; therefore, a properly adjusted observational analysis (conditioning on $Z$ but not on $M$ when targeting the total effect) can identify the causal effect under these assumptions, yet in the hierarchy of evidence it still sits below a randomized controlled trial because randomization would more generally remove all incoming arrows into $A$.**\n-   The statement that conditioning on $Z$ blocks all backdoor paths is consistent with our derivation.\n-   The statement that this leaves the causal paths open is correct.\n-   The instruction to condition on $Z$ but not on the mediator $M$ for the total effect is correct.\n-   The reasoning for why an RCT is higher in the evidence hierarchy is correct: randomization is a more robust mechanism for eliminating confounding.\n-   **Verdict:** Correct.\n\n**B. Conditioning on $Z$ fails to block the backdoor path $A \\leftarrow L \\to Y$, so residual confounding by $L$ remains; hence, the observational estimate is biased and the hierarchy of evidence offers no advantage to randomized controlled trials in this setting.**\n-   This is incorrect. The path $A \\leftarrow L \\to Y$ does not exist in the specified DAG because the problem states $L$ does not directly affect outcomes ($Y$). The actual path involving $L$, $A \\leftarrow L \\to Z \\to Y$, *is* blocked by conditioning on $Z$.\n-   The claim that RCTs offer no advantage is fundamentally wrong.\n-   **Verdict:** Incorrect.\n\n**C. Conditioning on $Z$ opens a collider at $Z$ because $L \\to Z \\leftarrow A$, creating bias; instead, one should condition on $M$ to block backdoor paths and thereby achieve evidence equivalent to a randomized controlled trial.**\n-   This is incorrect. First, the path $L \\to Z \\leftarrow A$ requires an arrow $A \\to Z$, but the DAG specifies $Z \\to A$. Therefore, this specific collider path does not exist. The node $Z$ is a non-collider on all backdoor paths listed.\n-   The suggestion to condition on $M$ is incorrect. $M$ is a mediator, and conditioning on it would block a causal pathway, preventing estimation of the total effect.\n-   The claim of achieving evidence equivalent to an RCT is false.\n-   **Verdict:** Incorrect.\n\n**D. Conditioning on $Z$ blocks the backdoor paths but also blocks the causal pathway through $M$; thus, to recover the total causal effect, one must additionally condition on $M$, which elevates the observational evidence to the same level as a randomized controlled trial in the hierarchy of evidence.**\n-   This is incorrect. Conditioning on $Z$ does *not* block the causal path $A \\to M \\to Y$ because $Z$ is not on that path.\n-   The recommendation to condition on $M$ to \"recover\" the total effect is the opposite of the correct procedure.\n-   The claim of elevating the evidence to the level of an RCT is false.\n-   **Verdict:** Incorrect.", "answer": "$$\\boxed{A}$$", "id": "4598909"}, {"introduction": "Even when a \"gold-standard\" randomized controlled trial (RCT) provides a reliable estimate of a treatment's effect, our work is not done. To inform clinical decisions, we must translate this evidence into practical, understandable metrics. This exercise demonstrates how to calculate various measures of effect and explores the crucial concept of transportability—specifically, how the clinical utility of an intervention, measured by the Number Needed to Treat ($NNT$), depends on the baseline risk of the population. [@problem_id:4800648]", "problem": "A consortium of trialists synthesizes high-quality randomized controlled trials (RCTs), which occupy the top of the hierarchy of medical evidence for estimating causal treatment effects. In a clinically homogeneous stratum of patients, they report the event risk under control $p_0=0.10$ and the event risk under treatment $p_1=0.07$. Using only core definitions of absolute and relative measures of effect applicable to RCTs, compute the risk difference $\\mathrm{RD}$, the relative risk $\\mathrm{RR}$, the odds ratio $\\mathrm{OR}$, and the number needed to treat $\\mathrm{NNT}$. Round $\\mathrm{RD}$, $\\mathrm{RR}$, $\\mathrm{OR}$, and $\\mathrm{NNT}$ to four significant figures and express $\\mathrm{NNT}$ as a pure number. Then, assuming the relative risk is fixed at a parameter $\\rho \\in (0,1)$, derive the closed-form expression for $\\mathrm{NNT}(p_0)$ as a function of the baseline risk $p_0$ and $\\rho$; do not round this expression. Report your answers in the order: $\\mathrm{RD}, \\mathrm{RR}, \\mathrm{OR}, \\mathrm{NNT}, \\mathrm{NNT}(p_0)$. In your reasoning, explain how changes in baseline risk $p_0$ affect $\\mathrm{NNT}(p_0)$ for fixed $\\rho$ in the context of transporting RCT evidence across populations in the hierarchy of medical evidence.", "solution": "The problem asks for the calculation of several standard measures of treatment effect from a randomized controlled trial (RCT), followed by a derivation of a functional relationship for the number needed to treat ($\\mathrm{NNT}$). The problem is well-posed and scientifically grounded in the principles of epidemiology and evidence-based medicine.\n\nWe are given the event risk in the control group, $p_0 = 0.10$, and the event risk in the treatment group, $p_1 = 0.07$. We first define the required measures of effect and then compute their values.\n\nThe Risk Difference ($\\mathrm{RD}$) is the absolute difference in risk between the two groups. By convention, it is calculated as the risk in the treated (or exposed) group minus the risk in the control (or unexposed) group.\n$$\n\\mathrm{RD} = p_1 - p_0\n$$\nA negative $\\mathrm{RD}$ indicates that the treatment reduces the risk of the event.\n\nThe Relative Risk ($\\mathrm{RR}$) is the ratio of the risk in the treatment group to the risk in the control group.\n$$\n\\mathrm{RR} = \\frac{p_1}{p_0}\n$$\nAn $\\mathrm{RR} < 1$ indicates a reduced risk in the treatment group.\n\nThe Odds Ratio ($\\mathrm{OR}$) is the ratio of the odds of an event in the treatment group to the odds of an event in the control group. The odds of an event for a given risk $p$ is defined as $p / (1-p)$.\n$$\n\\mathrm{OR} = \\frac{\\text{Odds}_1}{\\text{Odds}_0} = \\frac{p_1 / (1-p_1)}{p_0 / (1-p_0)} = \\frac{p_1(1-p_0)}{p_0(1-p_1)}\n$$\nAn $\\mathrm{OR} < 1$ indicates that the odds of the event are lower in the treatment group.\n\nThe Number Needed to Treat ($\\mathrm{NNT}$) is the reciprocal of the Absolute Risk Reduction ($\\mathrm{ARR}$). The $\\mathrm{ARR}$ is the absolute difference in risks, defined as $\\mathrm{ARR} = p_0 - p_1$, representing the reduction in risk attributable to the treatment. $\\mathrm{NNT}$ is interpreted as the average number of patients who must be treated to prevent one additional adverse event.\n$$\n\\mathrm{NNT} = \\frac{1}{\\mathrm{ARR}} = \\frac{1}{p_0 - p_1}\n$$\nThis quantity is meaningful only when the treatment is effective, i.e., $p_1 < p_0$.\n\nNow we compute the numerical values using the given data, $p_0 = 0.10$ and $p_1 = 0.07$, and round to four significant figures as requested.\n\nRisk Difference:\n$$\n\\mathrm{RD} = 0.07 - 0.10 = -0.03\n$$\nRounding to four significant figures gives $\\mathrm{RD} = -0.03000$.\n\nRelative Risk:\n$$\n\\mathrm{RR} = \\frac{0.07}{0.10} = 0.7\n$$\nRounding to four significant figures gives $\\mathrm{RR} = 0.7000$.\n\nOdds Ratio:\n$$\n\\mathrm{OR} = \\frac{0.07(1-0.10)}{0.10(1-0.07)} = \\frac{0.07 \\times 0.90}{0.10 \\times 0.93} = \\frac{0.063}{0.093} = \\frac{21}{31} \\approx 0.677419...\n$$\nRounding to four significant figures gives $\\mathrm{OR} = 0.6774$.\n\nNumber Needed to Treat:\n$$\n\\mathrm{NNT} = \\frac{1}{0.10 - 0.07} = \\frac{1}{0.03} = \\frac{100}{3} \\approx 33.333...\n$$\nRounding to four significant figures gives $\\mathrm{NNT} = 33.33$.\n\nNext, we derive the closed-form expression for $\\mathrm{NNT}(p_0)$ as a function of the baseline risk $p_0$, assuming the relative risk is fixed at a parameter $\\rho \\in (0,1)$.\nThe definition of relative risk is $\\rho = \\mathrm{RR} = p_1 / p_0$. This allows us to express the treatment risk $p_1$ in terms of the baseline risk $p_0$ and the fixed relative risk $\\rho$:\n$$\np_1 = \\rho p_0\n$$\nSubstituting this into the formula for $\\mathrm{NNT}$:\n$$\n\\mathrm{NNT}(p_0) = \\frac{1}{p_0 - p_1} = \\frac{1}{p_0 - \\rho p_0}\n$$\nFactoring out $p_0$ from the denominator yields the final expression:\n$$\n\\mathrm{NNT}(p_0) = \\frac{1}{p_0(1 - \\rho)}\n$$\n\nFinally, we explain how changes in baseline risk $p_0$ affect $\\mathrm{NNT}(p_0)$ for a fixed relative risk $\\rho$. The derived expression $\\mathrm{NNT}(p_0) = \\frac{1}{p_0(1 - \\rho)}$ demonstrates an inverse relationship between the number needed to treat and the baseline risk. Since the treatment is protective, $\\rho \\in (0,1)$, which makes the term $(1-\\rho)$ a positive constant. Therefore, $\\mathrm{NNT}(p_0)$ is inversely proportional to $p_0$.\n\nThis relationship is of paramount importance when transporting evidence from RCTs to different clinical settings or populations, a common task in evidence-based medicine. RCTs might be conducted on a specific population, but the treatment may be considered for a broader population with a different baseline risk. While absolute measures like the Risk Difference are known to vary substantially with baseline risk, relative measures like the Relative Risk or Odds Ratio are often assumed to be more stable (or \"transportable\") across populations. Under this assumption of a constant $\\rho$, our formula shows that the absolute benefit of the treatment, as measured by $\\mathrm{NNT}$, is highly dependent on the baseline risk of the patient group. Specifically, as the baseline risk $p_0$ increases, the $\\mathrm{NNT}$ decreases. This means fewer patients need to be treated in a high-risk population to prevent one adverse event, making the intervention more efficient and cost-effective in that group. Conversely, in a low-risk population (small $p_0$), the $\\mathrm{NNT}$ will be very large, suggesting a much smaller absolute benefit and potentially questioning the value of the intervention for that specific group. This principle guides clinical decision-making and public health policies, often leading to recommendations that prioritize treatment for higher-risk individuals.", "answer": "$$\n\\boxed{\\begin{pmatrix} -0.03000 & 0.7000 & 0.6774 & 33.33 & \\frac{1}{p_0(1-\\rho)} \\end{pmatrix}}\n$$", "id": "4800648"}]}